Babarczy Julian Michael 4

What Happened
Julian Michael Babarczy, a Director of Alterity Therapeutics Ltd (ATHE), received a grant of 2,000,000 derivative shares on 2026-06-15. The Form 4 lists this as a Grant/Award (code A) with an acquisition price of $0, so the reported transaction value is $0. This is a compensation-type award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-15; filing date: 2026-06-23 (filed 8 days after the transaction). Form 4s are generally required within 2 business days, so this filing appears later than the typical deadline.
• Instrument: Derivative equity (award/grant). Acquisition price reported as $0.
• Shares reported acquired: 2,000,000.
• Shares owned following the transaction: not specified in the provided summary (not reported here).
• No footnotes or a 10b5-1 plan, vesting schedule, or tax-withholding details were disclosed in the summary provided.

Context
Derivative awards like this are commonly RSUs or performance/share-based grants that vest over time or on achievement of milestones; they are compensation, not a cash purchase, and do not necessarily indicate the insider is increasing or decreasing personal exposure to the stock. Because the award was granted at $0, its immediate reported monetary value is $0 on the Form 4, though market value depends on ATHE's trading price and any vesting conditions.